Clearmind Medicine Inc. is a Canada-based psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Companyâs intellectual portfolio consists of fourteen patent families. The Company’s portfolio consists of patent families, such as alcoholic beverage substitute and binge behaviour regulators.
Clearmind Medicine Brief: Says Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange -March 13, 2024 at 10:17 am EDT
Date:


